Representing estates and facilities professionals operating within the  
 
 

News

 
28
Jan

NICE to begin technology appraisals


Department of Health ministers have agreed to refer the following topics to the National Institute for Health and Clinical Excellence (NICE) in December, to begin the process of developing guidance for each topic.

The following technology appraisals have been referred to NICE.

  • To appraise the clinical and cost effectiveness of afatinib for the treatment of epidermal growth factor receptor mutation positive locally advanced or metastatic non-small cell lung cancer.
  • To appraise the clinical and cost effectiveness of aflibercept within its licensed indication for the treatment of visual impairment due to macular oedema caused by central retinal vein occlusion.
  • To appraise the clinical and cost effectiveness of alemtuzumab within its licensed indication for the treatment of relapsing-remitting multiple sclerosis.
  • To appraise the clinical and cost effectiveness of dimethyl fumarate within its licensed indication for the treatment of relapsing-remitting multiple sclerosis.
  • To appraise the clinical and cost effectiveness of laquinimod within its licensed indication for the treatment of relapsing-remitting multiple sclerosis.
  • To appraise the clinical and cost effectiveness of teriflunomide within its licensed indication for the treatment of relapsing forms of multiple sclerosis.
  • To appraise the clinical and cost effectiveness of dabrafenib within its licensed indication for the treatment of unresectable, advanced or metastatic BRAFV600 mutation-positive melanoma.
  • To appraise the clinical and cost effectiveness of radium-223 dichloride within its licensed indication for the treatment castration-resistant prostate cancer with bone metastases.
  • To appraise the clinical and cost effectiveness of sipuleucel-T within its licensed indication for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.
  • To appraise the clinical and cost effectiveness of ustekinumab within its licensed indication for the treatment of active and progressive psoriatic arthritis.

 

Archive